Program Code: SCF-VHI-RSV1-0010
Framework: SCF Interactomics + Multi-Omic Host–Pathogen Interface Engineering
SECTION I — SCOPE & OBJECTIVE
1.1 Objective
To construct a high-resolution Viral–Host Interactome Map for RSV-1, defining:
- Viral protein ↔ host protein interaction networks
- Cellular pathway hijacking mechanisms
- Cross-omic disruption cascades
- SCF-targetable intervention nodes
SECTION II — RSV–HOST INTERACTOME ARCHITECTURE
2.1 Core Viral Proteins Involved
Viral Protein | Function | Interactome Role |
G protein | Host attachment | Receptor engagement |
F protein | Membrane fusion | Cytoskeletal remodeling |
NS1 | IFN suppression | Immune signaling blockade |
NS2 | IFN suppression | STAT pathway interference |
L protein (RdRp) | RNA replication | Host metabolic hijacking |
M protein | Assembly | Intracellular trafficking |
2.2 Host System Layers Targeted
System | Primary Impact |
Immune System | Interferon suppression |
Epithelial Barrier | Cell fusion, structural collapse |
Metabolic System | ATP depletion |
Cytoskeleton | Syncytia formation |
Neural–Respiratory Axis | Hypoxia signaling |
SECTION III — MOLECULAR INTERACTION NETWORK (PROTEIN–PROTEIN)
3.1 Viral–Host Binding Map
Viral Protein | Host Target | Interaction Type | Outcome |
G protein | CX3CR1 receptor | Ligand binding | Viral attachment |
F protein | Membrane phospholipids | Fusion complex | Syncytia formation |
NS1 | RIG-I / MAVS | Inhibition | IFN suppression |
NS2 | STAT2 | Degradation | Immune evasion |
L protein | Host ribonucleoproteins | Co-option | RNA replication |
M protein | Cytoskeletal proteins | Binding | Viral assembly |
3.2 SIGNALING PATHWAY HIJACKING
Pathway | Viral Strategy | Effect |
Interferon (IFN) | NS1/NS2 inhibition | Immune suppression |
NF-κB | Dysregulation | Inflammation |
MAPK | Activation | Viral replication support |
PI3K-AKT | Activation | Cell survival (prolong infection) |
SECTION IV — MULTI-OMIC INTERACTOME CASCADE
Aligned with SCF Pathophysiology Protocol
Omics Layer | Viral Interaction | Host Outcome |
Genomics | Viral RNA replication | Host gene expression disruption |
Transcriptomics | IFN suppression | Reduced antiviral response |
Proteomics | Viral protein binding | Signal pathway alteration |
Metabolomics | Glycolysis ↑ | Energy depletion |
Epigenomics | Immune gene silencing | Chronic susceptibility |
Microbiomics | Airway disruption | Secondary infection risk |
Connectomics | Hypoxia signaling | Autonomic imbalance |
SECTION V — CELLULAR INTERACTOME TOPOLOGY
5.1 Primary Cell Targets
Cell Type | Interaction |
Ciliated epithelial cells | Viral entry + replication |
Type II pneumocytes | Surfactant disruption |
Macrophages | Immune dysregulation |
Dendritic cells | Antigen presentation inhibition |
5.2 Subcellular Interaction Nodes
Organelle | Viral Interaction | Effect |
Plasma membrane | Fusion (F protein) | Cell-cell syncytia |
Cytoplasm | RNA replication (L protein) | Viral amplification |
Mitochondria | RIG-I signaling interference | Immune suppression |
Cytoskeleton | Actin remodeling | Viral spread |
SECTION VI — INTERACTOME CASCADE FLOW (SCF LOGIC)
G Protein Binding → F Protein Fusion →
NS1/NS2 Immune Suppression →
RdRp Replication →
Cytoskeletal Remodeling →
Syncytia Formation →
Immune Dysregulation →
Tissue Damage
SECTION VII — CRITICAL INTERACTION HUBS (HIGH-VALUE TARGETS)
7.1 Hub Classification
Hub | Type | Importance |
CX3CR1 receptor | Entry | High |
F protein fusion complex | Structural | Critical |
RIG-I / MAVS | Immune | Critical |
STAT2 | Immune signaling | High |
PI3K-AKT pathway | Survival | Moderate |
7.2 Network Vulnerability Analysis
- Central hubs: F protein, NS1/NS2
- Bottleneck nodes: RIG-I, STAT2
- Amplification nodes: MAPK, NF-κB
SECTION VIII — SCF THERAPEUTIC TARGET MAPPING
8.1 Direct Viral Targets
Target | Strategy |
F protein | Fusion inhibitors |
G protein | Attachment blockers |
RdRp (L protein) | Replication inhibitors |
8.2 Host-Directed Targets
Target | Strategy |
Interferon pathway | IFN agonists |
STAT signaling | Stabilization |
Mitochondria | Bioenergetic support |
Cytoskeleton | Fusion inhibition modulation |
SECTION IX — INTERACTOME-BASED RESISTANCE MODEL
9.1 Resistance Risk
Target Type | Risk |
Viral proteins | Mutation-driven escape |
Host pathways | Lower resistance risk |
9.2 SCF STRATEGY
- Combine:
- Viral inhibition (F + RdRp)
- Host pathway modulation
→ High-barrier resistance architecture
Aligned with SCF principles
SECTION X — CO-INFECTION INTERACTOME OVERLAY (RSV + CICADA VARIANT)
Interaction Layer | Amplification |
Entry | Dual receptor usage |
Immune | Severe IFN suppression |
Metabolic | Accelerated ATP depletion |
Structural | Severe lung damage |
SECTION XI — STRATEGIC RESEARCH PATHWAYS
11.1 Experimental
- Proteomics-based interactome mapping (mass spectrometry)
- CRISPR knockdown of host interaction nodes
11.2 Computational
- Network centrality analysis
- Dynamic interactome simulation
11.3 Translational
- Host-targeted antivirals
- SCF-designed fusion inhibitor APIs
SECTION XII — INTEGRATED SCF INTERACTOME SUMMARY
RSV-1 pathogenesis is driven by:
- High-efficiency viral–host protein interaction networks
- Central immune suppression nodes (NS1/NS2)
- Fusion-driven cellular restructuring
- Metabolic and signaling pathway hijacking
Critical insight:
→ Targeting interactome hubs provides superior therapeutic leverage vs single viral targets
MASTER REGISTRY INDEX
- SCF-VHI-RSV1-0010
- SCF-VIR-TIER-RSV1-0009
- SCF-VOA-RSV1-0008
- SCF-PATHO-RSV1-0004
- SCF-PATHO-EXT-0001
- SCF-SEF-MD-0001
- SCF-SCP-PRINCIPLES-0001
Next Module Options
- SCF RSV Fusion Inhibitor API (full drug design + SMILES)
- Interactome-driven drug target prioritization model
- RSV–COVID dual interactome convergence mapping